Your Position: Home > Journal List > China Medicine > Paper

The plasmatic activity changes of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in patients with acute exacerbation of chronic obstructive pulmonary disease

( views:169, downloads:0 )
Author:
XIN Ping(Respiration Foundation Laboratory, Beijing Institute of Respiratory Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China)
PANG Bao-sen(Respiration Foundation Laboratory, Beijing Institute of Respiratory Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China)
ZHANG Hai-yan(Respiration Foundation Laboratory, Beijing Institute of Respiratory Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China)
HUANG Xiu-xia(Respiration Foundation Laboratory, Beijing Institute of Respiratory Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China)
GUO Su-liang(Respiration Foundation Laboratory, Beijing Institute of Respiratory Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China)
Journal Title:
China Medicine
Issue:
Volume 07, Issue 02, 2012
DOI:
10.3760/cma.j.issn.1673-4777.2012.02.005
Key Word:
Pulmonary disease, chronic obstructive;Plasminogen activator;Plasminogen activator inhibitor 1

Abstract: Objective To explore clinical significances of plasma tissue-type plasminogen activator(t-PA) and type 1 plasminogen activator inhibitor ( PAI-1 ) in acute exacerbation of chronic obstructive pulmonary disease (AECOPD).Methods Two hundred and three patients hospitalized with AECOPD from 2007 to 2010 were chosen as the AECOPD group,while 142 normal persons receiving general health check-up during the same period were arranged for normal control group.Results The value of plasma t-PA in AECOPD patients was significantly lower than that in the normal control group [ (4.4 ± 4.1 ) μg/L vs (7.3 ± 1.4) μg/L,P < 0.01 ] ; and the value of plasma PAI-1 in AECOPD patients was significantly higher than that in the normal control group[ (42 ± 14) μg/L vs ( 19 ±9) μg/L,P < 0.01 ].Conclusions The blood of patients with AECOPD is in a hypercoagulation state,which can easily result in thrombosis of small pulmonary arteries and arterioles.The detection of plasma t-PA and PAI-1 has a certain clinical significance in discovering if there is a hypercoagulation state in AECOPD patients in the early stage.

  • [1]邱建,钱学贤,刘映峰,等.冠心病组织型纤溶酶原激活物及其抑制剂的活性变化.中华内科杂志,1996,35(12):830-831.
  • [2]党京丹.血栓前状态与临床疾病相关性的分析.当代医学,2008,14(5):21-22.
  • [3]王辰,杜敏捷,曹大德,等.慢性肺原性心脏病急性发作期肺细小动脉血栓形成的病理研究.中华医学杂志,1997,7(7):123-125.
  • [4]高原明,翁心植,陈世伦,等.慢性肺心病患者血小板功能的研究.中华结核和呼吸杂志,1998,21(7):404-406.
  • [5]李立宇,王辰,庞宝森,等.慢性阻塞性肺疾病急性期凝血纤溶系统功能变化的临床研究.中国实用内科杂志,2008,28(8):667-669.
  • [6]徐玉清,林荣青,王孟学,等.慢性肺源性心脏病急性发作期患者血液纤溶系统状态的变化.哈尔滨医科大学学报,1995,29(2):125-126.
  • [7]张川,袁高辉,韦凡平,等.肺源性心脏病心力衰竭患者的凝血纤溶系统活性变化.心脑血管病防治,2006,6(1):17-19.
  • [8]郑宏.慢性肺心病患者血清NO、NOS、TNF含量的变化及意义.放射免疫学杂志,2005,18(4):280-282.
  • [9]杜美蓉,戴长林.益气活血方对大鼠凝血-纤溶系统影响的实验.江苏中医药,2003,23(6):36-37.
  • [10]胡翊群,王鸿利,熊树民,等.现代血液学检验与临床实验.上海:上海科学技术出版社,1999:161-164.
  • [11]李家增.血栓病学.北京:科学出版社,1998:64-80.
  • [12]汪慧,王芳,何雯,等.脑梗死患者血浆t-Pa、PAI-1指标的观察.中风与神经疾病杂志,2003,20(3):278.
  • [13]郑文斐,邱娇娇,董仙萍,等.内皮细胞型纤溶酶原激活物抑制剂与盆腔粘连.中国医师进修杂志,2010,33(30):76-78.
  • [14]颜存粮,彭黎明,江虹,等.血栓性疾病实验诊断指标的应用研究.中国实验诊断学,2005,8(2):121-125.
  • [15]郑仁东,王学文.组织型纤溶酶原激活物抑制剂-1与糖尿病的关系.中国基层医药,2010,17(24):3425-3428.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn